Taub Institute: Genomics Core
AN NIA-FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER

 

Columbia University
Irving Medical Center
Neurological Institute

710 West 168th Street, 3rd floor
(212) 305-1818


bottom bar
top
make an appointment

Clinical Trials

Clinical Trials Currently Recruiting



Mild Cognitive Impairment/ Alzheimer’s Disease: GRADUATE gantenerumab (F. Hoffman-La Roche Ltd)
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease.
Phase 3. Subcutaneous Medication. Every 4 weeks. Duration: about 2 years. NCT03444870.
Mild Cognitive Impairment due to Alzheimer’s Disease (AD)/Mild Alzheimer’s Disease (AD). MMSE: ≥22. Age: 50-90.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Mild Cognitive Impairment/ Alzheimer’s Disease: CLARITY AD BAN2401 (Eisai)
A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease.
Phase 3. Intravenous infusion. Every 2 weeks. Duration: 18 months. NCT03887455.
Mild Cognitive Impairment due to Alzheimer’s Disease (AD)/Mild Alzheimer’s Disease (AD). MMSE: ≥22. Age: 50-90.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Mild Cognitive Impairment/ Alzheimer’s Disease: DISCOVER Posiphen® (QR Pharma Inc.)
Safety, Tolerability, PK and PD of Posiphen® in Subjects with Early Alzheimer’s Disease.
Phase 1/2. Oral Medication. Three times daily. Duration: about 1 month. NCT02925650.
Mild Cognitive Impairment due to Alzheimer’s Disease (AD)/Mild Alzheimer’s Disease (AD). MMSE: 21-27. Age: 55-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Mild Cognitive Impairment/ Alzheimer’s Disease: PEGASUS AMX0035 (Amylyx Pharm/ADDF/Alz Asso)
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease.
Phase 2. Oral Medication. Once then twice daily. Duration: about 32 weeks. NCT03533257.
Mild Cognitive Impairment due to Alzheimer’s Disease (AD)/Mild Alzheimer’s Disease (AD). MoCA: 8-26. Age: 55-89.
(Dr. Bell) Call Ruth Tejeda 212-305-7661

UPCOMING STUDY: Alzheimer’s Disease: AL002 (Alector Inc)
A Phase I Study for Safety and Tolerability of AL002.
Phase 1. IV Infusion. 15 visits including 2 infusions. Duration: about 26 weeks. NCT03635047.
AD. MMSE: 16-28. Age: 50-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

UPCOMING STUDY: Alzheimer’s Disease: AL003 (Alector Inc)
First in Human Study for Safety and Tolerability of AL003.
Phase 1. IV Infusion. 15 visits including 2 infusions. Duration: about 26 weeks. NCT03822208.
AD. MMSE: 16-28. Age: 50-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Mild Cognitive Impairment: Computerized Cognitive Training (NIA)
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment.
Interventional Trial. Computerized Cognitive Training. Duration: 78 weeks. NCT03205709.
Mild Cognitive Impairment (MCI). MMSE 23-30. Ages 55-95.
(Dr. Devanand) Call Jessica D’Antonio 646-774-8674

Alzheimer’s disease: VALAD valacyclovir (NIH/NIA)
Anti-viral therapy in Alzheimer’s disease.
Phase 2. Oral Medication. Twice daily. Duration: 78 Weeks (18 months). NCT03282916.
Mild Alzheimer’s disease (AD); positive screening tests results for antibodies to HSV1 or HSV2. MMSE: 20-28. Age 55-95.
(Dr. Devanand) Call Julianna Pollina 646-774-8638

Alzheimer's Disease: S-CitAD escitalopram (NIA)
Escitalopram for Agitation in Alzheimer’s Disease.
Phase 3. Combination intervention; Psychosocial Intervention and Oral Medication. Duration: 24 Weeks (6 months). NCT03108846.
Alzheimer's disease (AD) with agitation. MMSE: 5-28. Age 55-95.
(Dr. Devanand) Call Laura Simonpearson 646-774-8671

Frontotemporal Dementia: lithium (ADDF)
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia.
Phase 2/3. Oral Medication. Once daily. Duration: 12 Weeks. NCT02862210.
Frontotemporal Dementia (FTD). MMSE: 5-26. Age: 40-85
(Dr. Huey) Call Hannah Silverman (212) 305-6284

Frontotemporal Dementia: FOXY
A Phase 2 Clinical Trial of Oxytocin for Frontotemporal Dementia.
Phase 2/3. Intranasal spray. Twice daily. Duration: 24 Weeks. NCT03260920.
Frontotemporal Dementia (FTD). MMSE: >10. Age: 30-80
(Dr. Huey) Call Hannah Silverman (212) 305-6284

UPCOMING STUDY: Frontotemporal Dementia: AL001 (Alector Inc)
A Study to Evaluate Safety of Long-term AL001 Dosing in FTD Patients.
Phase 2. IV Infusion every 4 weeks. Duration: about 48 weeks. NCT03987295.
FTD. Carrier of a loss of function GRN mutation or carrier of a hexanucleotide repeat expansion C9orf72 mutation. CDR 0, 0.5, 1, or 2. Age: 18-80.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Observational Studies Currently Recruiting



Mild Cognitive Impairment/ Mild Alzheimer’s Disease/ Normal Cognition: ADNI3 (NIH/NIA)
Alzheimer’s Disease Neuroimaging Initiative 3
Duration: 2. NCT02854033
Mild Cognitive Impairment/Mild Alzheimer’s Disease/Normal Cognition. MMSE: ≥24 (CN and MCI) 20-24 (AD). Age: 55-90.
(Dr. Stern) Call Anton Kociolek 212-342-0522

Mild Cognitive Impairment: ADRC Project 1(NIH/NIA)
White Matter and Hippocampal Circuitry
Duration: 2 visits, 2.5hrs each visit.
Mild Cognitive Impairment (MCI). CDR 0 or 0.5. Age: ≥60.
(Dr. Brickman) Call Christiane Hale 646-317-4072

Mild Cognitive Impairment/Early Onset Alzheimer’s Disease/Normal Cognition: LEADS (NIH/NIA)
Longitudinal Early Onset Alzheimer’s Disease
Duration: 2 years, yearly visit.
Mild Cognitive Impairment/Early Onset Alzheimer’s Disease/Normal Cognition. CDR 0.5 or 1.0 (MCI/AD). Age: 40-64.
(Dr. Honig) Call Arlene Mejia 212-305-9168

Mild Alzheimer's Disease/Amnestic Mild Cognitive Impairment/Normal Cognition: Autoimmune (NIH/NINDS)
Autoimmune features in neurodegenerative disorders
Duration: 1 to 2 visits. 1.5hrs per visit
Mild Alzheimer's Disease/Amnestic Mild Cognitive Impairment/Normal Cognition. MMSE: 20-26. Age: ≥55
(Dr. Marder) Call Heather Xu 646-774-5023

Alzheimer’s Disease: DIAN (NIH/NIA)
Dominantly Inherited Alzheimer Network
Duration: Years. Every 1 to 3 years visits.
Family members of a person with AD (proband) due to PSEN1, PSEN2, or APP mutations. MMSE: any. Age: ≥18; younger but no more than 10 years younger than proband’s AAO.
(Dr. Noble) Call Dolly Reyes-Dumeyer 212-305-5953, Katie Neimeyer 212-305-5909

Alzheimer’s Disease: EFIGA (NIH/NIA)
Genetic Study of Alzheimer’s Disease in Caribbean Hispanics
Duration: 1.5 hours visit (in person). Visits are every 2 years for the duration of the study.
Hispanic families with multiple affected alive-siblings (2+) and an additional individual healthy or not, willing to participate. Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Angel Piriz 212-305-2309

Alzheimer’s Disease: LOAD (NIH/NIA)
Late Onset Alzheimer’s Disease
Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study.
Any ethnic background families with multiple affected alive-siblings (2+) and an additional individual healthy or not, willing to participate; Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Izri Martinez (For African American participants) 212-305-2349

Alzheimer’s Disease: READR (NIH/NIA)
Resource for Early Onset Alzheimer’s Disease Research: Early Onset Alzheimer’s Disease Whole Genome Sequencing
The goal is to identify unknown mutations (other than APP, PSEN1 and PSEN2) Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study.
Age: Onset of memory problems before the age of 65.
(Dr. Reitz) Call Penelope Baez 201-640-4335

Alzheimer’s Disease: Naming Study (NIH/NINDS)
Assessment and Characterizationof Naming in Older Adults with Epilepsy and PAD
Duration: 1 visit. 90 minutes.
Probable Alzheimer’s Disease. MMSE: 19-25. Age: 56-90.
(Dr. Hamberger/Dr. Honig) Call Alicia Williams 212-305-1801

Alzheimer's Disease: Apathy in Alzheimer's Disease (DOD/NIA)
Investigating a New Biological Pathway for Treatment Targeting to Positively Impact Quality of Life
Duration: 1 visit. 2 hours.
Alzheimer's Disease. MMSE: 9-26. Age: any.
(Dr. Clelland) Call Bimala Rawal 212-304-7722

Subjective Cognitive Complaint: SCD Project (NIH/NIA)
Characterizing Subjective Cognitive Decline in Older Adults
Duration: 1 visit. 1.5hrs.
Subjective Cognitive Complaint. Age: ≥56.
(Dr. Cosentino) Call Jillian Joyce 212-342-1969

Neurodegenerative diseases/Mild Cognitive Impairment/Normal Cognition: NAPS (NIH)
Neurodegeneration-Associated Psychiatric Symptoms
Duration: 1 visit, 4-5 hours.
Alzheimer's disease, Frontotemporal dementia, Primary Progressive Aphasia, Dementia with Lewy Bodies, Parkinson’s disease, Huntington's disease, Mild Cognitive Impairment, Healthy Controls. Age: 40-85. (Dr. Huey) Call Yedili Genao-Perez 212-305-3187

Dementia with Lewy Bodies: Targeting Lewy Body Pathology (NIH/NINDS)
Targeting Lewy Body Specific Pathology Using Biomarkers
Duration: 5 years.
Dementia with Lewy Bodies. Age: ≥65.
(Dr. Marder/Dr. Honig) Call Helen Mejia-Santana 212- 305-9183, Kate Smith 212-305-8873

Programs Currently Recruiting


Arts and Minds
The Studio Museum in Harlem, New York Historical Society, and El Museo del Barrio
Excluded: persons with depression (only), cognitively normal persons, and patients with dementia in whom agitation is severe and dominating care. Spanish-speakers are welcome. Participants will explore the world of art and culture in these interactive 75-minute programs.
(Dr. Noble) Call Carolyn Halpin-Healy 646-755-3726

A Friend for Rachel
A companionship program
MCI, early AD, early PPA, FTD (if not too behavioral), early DLB (if no hallucinations).
Must be mobile and able to go out of home without an aide.
Participants will spend a few hours a week with their student friend either exploring NYC or staying near home.
Call Jill Goldman 212-305-7382

bottom bar